# Epitel

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epitel

- Industry: Medical Devices & Equipment
- Headquarters: Salt Lake City, US
- Website: www.epitel.com
- Total disclosed funding: $39M
- Latest round: Series B (Jul 28, 2026)
- Investors on record: 7

## About

Based in Utah, US, and founded in 2014 by CEO/CTO Mark Lehmkuhle, Epitel, Inc. operates as a digital health company that provides wearable devices that monitor patients' brain health. In July 2026, Epitel, Inc. raised USD 26 million in series B funding co-led by Catalyst Health Ventures and Genoa Ventures.

Epitel, Inc. provides REMI (remote EEG monitoring platform), a wearable wireless ECG monitoring platform that is used to diagnose, treat, and manage seizures within hospital emergency rooms as well as critical care units. REMI is FDA approved product that is placed in the scalp below the hairline to capture EEG with 4 epilog sensors and connected with Persyst or an app to read EEG and receive seizure insights.

The company will use the July 2026 funding to expand its REMI Remote EEG monitoring system and support seizure diagnosis

## Funding rounds

- Series B, Jul 28, 2026, $26M — Catalyst Health Ventures, Genoa Ventures
- Series A, Feb 16, 2022, $13M — Catalyst Health Ventures, Genoa Ventures, SLC Angels, OSF Ventures, Wavemaker Three-Sixty Health, Dexcom Ventures, MedMountain Ventures

## Investors

- Catalyst Health Ventures (https://capitalatlas.ai/funds/catalyst-health-ventures) — Series A, Series B
- Genoa Ventures (https://capitalatlas.ai/funds/genoa-ventures) — Series A, Series B
- SLC Angels — Series A
- OSF Ventures (https://capitalatlas.ai/funds/osf-ventures) — Series A
- Wavemaker Three-Sixty Health (https://capitalatlas.ai/funds/wavemaker-three-sixty-health) — Series A
- Dexcom Ventures (https://capitalatlas.ai/funds/dexcom-ventures) — Series A
- MedMountain Ventures (https://capitalatlas.ai/funds/medmountain-ventures) — Series A